Phenotype Variability in Interstitial Cystitis Clinical Trial Recruitment
Failure to incorporate IC/BPS phenotypes into trial design limits the ability to evaluate treatments within the context of real-world symptom variability. Bridging this methodological gap is essential to ensure that clinical research supports the development of more targeted and effective therapies.
Authors
- Annah Vollstedt (ORCID: https://orcid.org/0000-0002-1819-4275)
- Sarah A. Adelstein (ORCID: https://orcid.org/0000-0003-1784-0527)
- Ryan Wong (ORCID: https://orcid.org/0000-0002-1251-758X)
- Charles Cresson Wood
- Emmaline Woodworth
Institutions
- Nova Southeastern University (US)
- University of Iowa Hospitals and Clinics (US)
- New York Institute of Technology (US)
- Rush University (US)
Publication Details
- Journal
- Urogynecology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.1097/spv.0000000000001759
- Primary Topic
- Urinary Bladder and Prostate Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00